On February 25, 2025, Eli Lilly and Company announced the launch of 7.5 mg and 10 mg Tirzepatide (tirzepatide) single-dose vials, available for USD 499 with the new Tirzepatide Self Pay Journey Program
Some employers hold off on expanding GLP-1 coverage, for now Organizations are holding off on plans to cover GLP-1s for weight loss in the future, if they arent already doing so
Peak concentration timing After subcutaneous injection in the thigh, tirzepatide typically reaches peak blood concentration (Cmax) within 24-72 hours
The primary risks include gastrointestinal side effects (nausea, diarrhoea, vomiting) that may mask Crohn's flares, delayed gastric emptying potentially worsening strictures, dehydration leading to acute kidney injury, and appetite suppression that could worsen malnutrition in already underweight patients
For type 2 diabetes, approval applies to adults regardless of baseline weight if metabolic control is inadequate
10.1098/rsbl.2018.0842 Biol
